This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BOLD vs. ELDN, IVA, ANNX, CYBN, AARD, DSGN, NGNE, FULC, NBTX, and ACTUShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Eledon Pharmaceuticals (ELDN), Inventiva (IVA), Annexon (ANNX), Cybin (CYBN), Aardvark Therapeutics (AARD), Design Therapeutics (DSGN), Neurogene (NGNE), Fulcrum Therapeutics (FULC), Nanobiotix (NBTX), and Actuate Therapeutics (ACTU). These companies are all part of the "medical" sector. Audentes Therapeutics vs. Eledon Pharmaceuticals Inventiva Annexon Cybin Aardvark Therapeutics Design Therapeutics Neurogene Fulcrum Therapeutics Nanobiotix Actuate Therapeutics Audentes Therapeutics (NASDAQ:BOLD) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking. Does the media favor BOLD or ELDN? In the previous week, Audentes Therapeutics' average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score. Company Overall Sentiment Audentes Therapeutics Neutral Eledon Pharmaceuticals Neutral Does the MarketBeat Community prefer BOLD or ELDN? Audentes Therapeutics received 442 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 73.68% of users gave Eledon Pharmaceuticals an outperform vote while only 69.12% of users gave Audentes Therapeutics an outperform vote. CompanyUnderperformOutperformAudentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% Eledon PharmaceuticalsOutperform Votes2873.68% Underperform Votes1026.32% Which has better earnings & valuation, BOLD or ELDN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAudentes TherapeuticsN/AN/A-$49.43MN/AN/AEledon PharmaceuticalsN/AN/A-$116.54M-$2.36-1.27 Do analysts rate BOLD or ELDN? Audentes Therapeutics currently has a consensus target price of $23.00, suggesting a potential upside of 1,544.03%. Eledon Pharmaceuticals has a consensus target price of $12.50, suggesting a potential upside of 318.06%. Given Audentes Therapeutics' higher possible upside, research analysts plainly believe Audentes Therapeutics is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in BOLD or ELDN? 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 5.3% of Audentes Therapeutics shares are held by company insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is BOLD or ELDN more profitable? Eledon Pharmaceuticals' return on equity of -189.99% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Audentes TherapeuticsN/A -321.10% -40.02% Eledon Pharmaceuticals N/A -189.99%-28.17% SummaryEledon Pharmaceuticals beats Audentes Therapeutics on 6 of the 9 factors compared between the two stocks. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.60M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / BookN/A5.936.443.98Net Income-$49.43M$142.99M$3.21B$247.73M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics1.2272 of 5 stars$1.40-39.2%$23.00+1,544.0%-87.6%$44.60MN/A0.00207Gap UpELDNEledon Pharmaceuticals1.3206 of 5 stars$2.98+1.4%$12.50+319.5%+90.4%$176.05MN/A-1.4810Positive NewsIVAInventiva1.6686 of 5 stars$3.29-2.1%$10.40+216.1%+4.3%$172.65M$9.20M0.00100Gap DownANNXAnnexon2.587 of 5 stars$1.53+2.7%$18.67+1,120.0%-68.2%$167.86MN/A-1.4660Short Interest ↓News CoverageCYBNCybin1.5917 of 5 stars$7.70+13.2%$86.00+1,016.9%N/A$165.37MN/A-1.7650High Trading VolumeAARDAardvark TherapeuticsN/A$7.62+6.7%$31.50+313.4%N/A$165.32MN/A0.0018Gap DownDSGNDesign Therapeutics1.2847 of 5 stars$3.25+12.5%$8.00+146.2%-11.2%$164.05MN/A-3.8240News CoveragePositive NewsNGNENeurogene1.9915 of 5 stars$10.89-1.0%$47.20+333.4%-65.8%$162.59M$925,000.00-2.5590Gap DownFULCFulcrum Therapeutics2.0157 of 5 stars$2.92+8.6%$8.63+195.4%-54.0%$157.62M$80M-9.42100Short Interest ↓News CoveragePositive NewsGap UpNBTXNanobiotix1.8236 of 5 stars$3.33flat$8.00+140.2%-37.9%$156.95M$-11,609,000.000.00100Gap DownACTUActuate TherapeuticsN/A$8.00+4.4%$20.00+150.0%N/A$156.26MN/A0.0010News Coverage Related Companies and Tools Related Companies Eledon Pharmaceuticals Competitors Inventiva Competitors Annexon Competitors Cybin Competitors Aardvark Therapeutics Competitors Design Therapeutics Competitors Neurogene Competitors Fulcrum Therapeutics Competitors Nanobiotix Competitors Actuate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLD) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BOLD Stock Free BOLD Stock Alerts